Van Weelden WJ, Lalisang RI, Bulten J, et al. - Among patients with advanced or recurrent endometrial cancer, this investigation was carried out to improve hormonal therapy efficacy via associating immunohistochemical expression of estrogen (ER) and progesterone receptor (PR) and ER pathway activity scores to response to hormonal therapy. The participants had available biopsies obtained before initiating hormonal therapy. According to findings, substantial improvement in prediction of response to hormonal treatment in endometrial cancer was achieved with a 50% cut-off level for PR-IHC and by using a sequential test algorithm employing PR-IHC and ER pathway activity scores. Validation of the findings in the PROMOTE-prospective study is required.